Lead Sponsor

Glyscend, Inc.

Age

30 - 70 years

Sex

ALL

Healthy Volunteers

No

•Patients diagnosed with type 2 diabetes: hemoglobin A1c (HbA1c)) ≥ 6.0 and ≤ 8.5% at screening
•Body mass index (BMI) ≥ 18 and ≤ 40 at screening

•Treated with any prescription medication for the treatment of type 2 diabetes or weight loss other than metformin in the last 3 months prior to screening
•Use of any drug treatment that affects gastric pH
•Use of any drug treatment that affects gastrointestinal motility
•Fasting blood glucose \> 190 mg/dL
•Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the gastrointestinal (GI) tract or active disease within 12 months prior to screening
•History of any previous abdominal or intestinal surgery including endoscopic, open or laparoscopic thoracic or abdominal surgery, surgical resection of the stomach, small or large intestine
•Clinically significant medical condition as judged by the Investigator that could potentially affect study participation and/or personal well-being